Alzheimers Drugs Market, By Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonist, Combination Therapy, Pipeline Drugs), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Onli
Alzheimers Drugs Market, By Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonist, Combination Therapy, Pipeline Drugs), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
Alzheimer's disease is a progressive neurodegenerative disease that slowly destroys memory and cognitive skills. It is the most common cause of dementia among older people. Global Alzheimer's drugs market growth is driven by rising prevalence of Alzheimer's disease worldwide. According to WHO, around 50 million people globally have dementia with nearly 10 million new cases every year. Rising approval and launch of novel disease modifying drugs that target the underlying pathophysiology of Alzheimer's can drive the market growth over the forecast period.
Market Dynamics:
Global Alzheimer's drugs market growth is driven by rising geriatric population, increasing prevalence of Alzheimer's disease, introduction of novel disease modifying drugs, growing healthcare expenditure and rising awareness about the condition. However, high costs associated with drug R&D and failure of late stage clinical trials can hamper the market growth. Developing regions with large elderly populations an offer significant growth opportunities. Technological advancements in early diagnosis and advancements in understanding the disease pathology can also offer new opportunities.
Key Features of the Study:
This report provides in-depth analysis of the global Alzheimer's drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Alzheimer's drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Novartis AG, Zydus Lifesciences Ltd (CADILA), Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Amneal Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd, Cipla Ltd., Torrent Pharmaceuticals Ltd., Unichem laboratories ltd, Lannett Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global Alzheimer's drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alzheimer's drugs market
Detailed Segmentation-
By Drug Class
Cholinesterase Inhibitors
Donepezil
Rivastigmine
Galantamine
NMDA Receptor Antagonist
Memantine
Combination Therapy
Donepezil and Memantine
Pipeline Drugs
Aducanumab
Lecanemab
Donanemab
By Route of Administration
Oral
Parenteral
Others
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Region
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
Company Profiles:
AbbVie, Inc.
Teva Pharmaceuticals Ltd.
Eisai Co., Ltd.
Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
Novartis AG
Zydus Lifesciences Ltd (CADILA)
Sun Pharmaceutical Industries Ltd.
Reddy's Laboratories Ltd
Aurobindo Pharma Ltd
Amneal Pharmaceuticals Inc.
Macleods Pharmaceuticals Ltd.
Viatris Inc.
Lupin Ltd
Cipla Ltd.
Torrent Pharmaceuticals Ltd.
Unichem laboratories ltd
Lannett Inc.
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Product
Market Snapshot, By End User
Market Snapshot, By Region
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter’s Analysis
4. Global Active Implantable Medical Devices Market- Impact of Coronavirus (COVID-19) Pandemic
Overall Impact
Government Initiatives
COVID-19 Impact on the Market
5. Global Active Implantable Medical Devices Market, By Product, 2019 – 2031, (USD Bn)
Overview
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020 – 2031
Segment Trends
Implantable Cardioverter Defibrillators
Overview
Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Bn)
Implantable Cardiac Pacemakers
Overview
Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Bn)
Ventricular Assist Devices
Overview
Market Size and Forecast, and Y-o-Y Growth, 2019–2031, (USD Bn)